These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 33866029)
1. Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data. Lasica AB; Jaunmuktane Z; Fersht N; Kirkman MA; Dixon L; Hoskote C; Brandner S; Samandouras G World Neurosurg; 2021 Jul; 151():e217-e233. PubMed ID: 33866029 [TBL] [Abstract][Full Text] [Related]
2. The Role of Extent of Resection in IDH1 Wild-Type or Mutant Low-Grade Gliomas. Patel T; Bander ED; Venn RA; Powell T; Cederquist GY; Schaefer PM; Puchi LA; Akhmerov A; Ogilvie S; Reiner AS; Moussazadeh N; Tabar V Neurosurgery; 2018 Jun; 82(6):808-814. PubMed ID: 28945860 [TBL] [Abstract][Full Text] [Related]
3. Adult IDH wild-type lower-grade gliomas should be further stratified. Aibaidula A; Chan AK; Shi Z; Li Y; Zhang R; Yang R; Li KK; Chung NY; Yao Y; Zhou L; Wu J; Chen H; Ng HK Neuro Oncol; 2017 Oct; 19(10):1327-1337. PubMed ID: 28575485 [TBL] [Abstract][Full Text] [Related]
4. Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas. Keric N; Krenzlin H; Kalasauskas D; Freyschlag CF; Schnell O; Misch M; von der Brelie C; Gempt J; Krigers A; Wagner A; Lange F; Mielke D; Sommer C; Brockmann MA; Meyer B; Rohde V; Vajkoczy P; Beck J; Thomé C; Ringel F J Neurooncol; 2024 Mar; 167(1):133-144. PubMed ID: 38326661 [TBL] [Abstract][Full Text] [Related]
5. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas. Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843 [TBL] [Abstract][Full Text] [Related]
6. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154 [TBL] [Abstract][Full Text] [Related]
7. Comparative Analysis of the Prognostic Significance of IDH,TERT, EGFR and MGMT Status in Patients with Adult Non-H3-Altered Grade 4 Gliomas: A Prospective Cohort Study. Alimohamadi M; Larijani A; Pour-Rashidi A; Farzin M; Ebrahimi H; Rahmani M; Hendi K; Yarandi KK; Aghajanian S; Shirani M World Neurosurg; 2024 Jan; 181():e628-e639. PubMed ID: 37914076 [TBL] [Abstract][Full Text] [Related]
8. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624 [TBL] [Abstract][Full Text] [Related]
9. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526 [TBL] [Abstract][Full Text] [Related]
10. Isocitrate Dehydrogenase Mutations in Low-Grade Gliomas Correlate With Prolonged Overall Survival in Older Patients. Jones PS; Carroll KT; Koch M; DiCesare JAT; Reitz K; Frosch M; Barker FG; Cahill DP; Curry WT Neurosurgery; 2019 Feb; 84(2):519-528. PubMed ID: 29846690 [TBL] [Abstract][Full Text] [Related]
11. Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype. Patel SH; Bansal AG; Young EB; Batchala PP; Patrie JT; Lopes MB; Jain R; Fadul CE; Schiff D AJNR Am J Neuroradiol; 2019 Jul; 40(7):1149-1155. PubMed ID: 31248860 [TBL] [Abstract][Full Text] [Related]
12. Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas. Rossi M; Gay L; Ambrogi F; Conti Nibali M; Sciortino T; Puglisi G; Leonetti A; Mocellini C; Caroli M; Cordera S; Simonelli M; Pessina F; Navarria P; Pace A; Soffietti R; Rudà R; Riva M; Bello L Neuro Oncol; 2021 May; 23(5):812-826. PubMed ID: 33049063 [TBL] [Abstract][Full Text] [Related]
13. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas. Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441 [TBL] [Abstract][Full Text] [Related]
15. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
16. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma. Karsy M; Guan J; Huang LE J Neurosurg; 2019 Jan; 130(1):56-66. PubMed ID: 29547090 [TBL] [Abstract][Full Text] [Related]
17. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas. Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906 [TBL] [Abstract][Full Text] [Related]
18. Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016. Compes P; Tabouret E; Etcheverry A; Colin C; Appay R; Cordier N; Mosser J; Chinot O; Delingette H; Girard N; Dufour H; Metellus P; Figarella-Branger D J Neurooncol; 2019 May; 142(3):511-520. PubMed ID: 30756272 [TBL] [Abstract][Full Text] [Related]
19. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas. Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038 [TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data. Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]